The Incannex (ASX:IHL) share price has lost 20% in 4 weeks. What's happening?

Incannex shares recently reversed their upward momentum. Read on for more details.

| More on:
A woman holds her hands to her face in shock and fear with a worried expression on her face

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Incannex Healthcare Ltd (ASX: IHL) share price has taken a beating over the past four weeks, having come off its all-time high of 44.5 cents on 2 September.

Prior to this, Incannex shares rallied from mid-August until this point. So, what's happened to reverse the climb for this medicinal cannabis company?

Read on for more details.

What's up with the Incannex share price lately?

The Incannex share price soared in August after the company advised it had filed an F-1 Registration form with the US Securities and Exchange Commission (SEC).

An F-1 registration is like an initial public offering (IPO) on the ASX, except it is reserved for companies domiciled outside of the US.

The key difference is that F-1 applicants complete a US public offering of American Depositary Shares (ADS) instead.

Each ADS represents 50 Incannex shares and trades on the American exchanges just like any ordinary share would.

Incannex shares jumped from 27.5 cents on the day of the announcement to an all-time high a few weeks later. 

But Incannex shares cooled off as September began, coinciding with the time it released its FY21 earnings results.  

In its report, the company recognised a 214% year over year increase in revenue, but this didn't carry through to its net profit after tax (NPAT).

In fact, the company recorded an almost 74% loss from ordinary activities that mushroomed to $8.2 million. As such, the company's net loss for the year ballooned 82% deeper into the red from FY20.

Investors weren't impressed by the healthcare company's results at all. In the days following the release, the Incannex share price started its march south.

So, it appears that investor sentiment has shifted for Incannex as selling pressures mount on its share price.

Share price snapshot

At the time of writing, Incannex is trading at 35 cents, down 2.82% today. That's also a 21% loss over 4 weeks.

On a longer-term view, the Incannex share price has been a major outperformer over the past year to date, climbing 130% into the green.

That builds to a 331% return over the past 12 months for Incannex shareholders. This is well ahead of the 25% gains recorded by the S&P/ASX 200 Index (ASX: XJO) over the past year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man looking happy and excited as he looks at his mobile phone.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on big news

This stock is getting a lot of attention from investors on Wednesday. But why?

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

How much further upside is there for Mesoblast shares after soaring 23% in a month?

Could FDA approval send this healthcare stock towards further gains?

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Is this soaring ASX 200 healthcare share just getting started?

If its lead therapy gets US approval, the stock can continue to climb.

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Own CSL shares? Here are the key dates for 2026

It's been a bad year for CSL shares. What's ahead in 2026?

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Healthcare Shares

Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Investors are piling into the ASX 300 healthcare share on Tuesday. Let’s see why.

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Healthcare Shares

Is Sigma Healthcare share a healthy buy, after hitting new lows?

The Chemist Warehouse merger and ageing population might boost this stock's appeal.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Telix shares fall despite 'significant milestone'

Let's see what the biotech has announced on Monday.

Read more »